U.S. DISEASES

U.S. Diabetes News

U.S. diabetes coverage follows treatment and monitoring developments, federal screening programs and the supply and pricing questions that determine access to care across the country. Reporting tracks approvals, research and the policy that shapes what patients can reach.

Monthly Obesity Drug Candidate Gets $1.5B Boost

Monthly Obesity Drug Candidate Gets $1.5B Boost

Adults with obesity and related conditions may see more monthly treatment options as late-stage trials advance.

Live Poll

Do you think new weight-loss drugs will ever be affordable for you?


Recent news


More in Diabetes

Day to day, that means drug and device approvals, federal prevention and screening program updates, research into Type 1 and Type 2 management, and monitoring technology developments. New York, Los Angeles, Chicago, Houston and Phoenix are among the centers where diabetes program activity and clinical research draw national reporting. Insulin pricing and supply chain dynamics recur as recurring structural subjects, because they directly determine whether approved treatments are within reach. Insurance coverage rules and formulary decisions shape access to monitoring technology as much as clinical approvals do.